This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Apollo Endosurgery Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

3.0%

Groei van de winst

21.2%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	1.9%
Rendement op eigen vermogen	-122.2%
Nettomarge	-51.8%
Laatste winstupdate	31 Dec 2022

Recente prestatie-updates uit het verleden

Recent updates

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Mar 03

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Feb 10

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Jan 31

Assessing Apollo Endosurgery

Dec 27

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Dec 27

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Dec 01

Apollo Endosurgery EPS beats by $0.10, beats on revenue

Nov 05

Opbrengsten en kosten

Hoe Apollo Endosurgery geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:APEN Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Dec 22	77	-40	57	12
30 Sep 22	72	-41	53	11
30 Jun 22	68	-36	50	11
31 Mar 22	66	-28	47	10
31 Dec 21	63	-25	43	10
30 Sep 21	60	-18	39	9
30 Jun 21	56	-14	35	8
31 Mar 21	45	-17	28	7
31 Dec 20	42	-23	28	8
30 Sep 20	41	-26	31	8
30 Jun 20	40	-32	34	8
31 Mar 20	48	-35	41	9
31 Dec 19	51	-27	42	10
30 Sep 19	54	-39	44	11
30 Jun 19	57	-40	45	13
31 Mar 19	58	-40	45	13
31 Dec 18	61	-46	46	12
30 Sep 18	62	-35	46	11
30 Jun 18	64	-30	47	10
31 Mar 18	66	-27	47	9
31 Dec 17	64	-27	47	8
30 Sep 17	64	-33	44	9
30 Jun 17	63	-36	44	9
31 Mar 17	63	-41	43	8
31 Dec 16	65	-41	42	8
30 Sep 16	66	-36	43	7
30 Jun 16	66	-38	44	8

Kwaliteitswinsten: APEN is currently unprofitable.

Groeiende winstmarge: APEN is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: APEN is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.

Versnelling van de groei: Unable to compare APEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: APEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.1%).

Rendement op eigen vermogen

Hoge ROE: APEN has a negative Return on Equity (-122.23%), as it is currently unprofitable.

This company has been acquired

Apollo Endosurgery Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Price target decreased to US$11.75

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Consensus forecasts updated

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus forecasts updated

Apollo Endosurgery, Inc. Announces Board Changes

Price target decreased to US$12.67

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold US$504k worth of stock

CEO, President & Director recently sold US$504k worth of stock

Chief Financial Officer recently bought US$219k worth of stock

Consensus forecasts updated

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Insider recently sold US$129k worth of stock

Price target increased to US$11.25

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

Apollo Endosurgery EPS beats by $0.05, beats on revenue

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Independent Chairman of the Board recently bought US$59k worth of stock

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

New 90-day high: US$6.10

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Insider recently bought US$86k worth of stock

Revenue beats expectations, earnings disappoint

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought US$146k worth of stock

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: US$4.86

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Assessing Apollo Endosurgery

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

New 90-day high: US$2.30

Analysts increase revenue estimates to US$40.2m

Third quarter 2020 earnings released: US$0.11 loss per share

Revenue beats expectations, earnings disappoint

Apollo Endosurgery EPS beats by $0.10, beats on revenue

New 90-day high: US$1.79

New 90-day low - US$1.31

First half earnings released